This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics
26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Dr. Michael Gold, MD
Chief R&D Officer at Compass Pathways
Speaker

Profile

Mike is a passionate and highly effective pharmaceutical executive, bringing more than 25 years of experience across all aspects of drug development in neuroscience to Compass. Before joining Compass, he was Chief Medical Officer at Neumora Therapeutics.

Mike has substantial therapeutic experience in neurological disorders and psychiatric disorders, including depression. He has worked extensively with small molecules, biologicals, drug-device combinations, diagnostics and various types of biomarkers. He has significant experience in all segments of the pharmaceutical/biotechnology sector, including large, small, specialty, start-up and CRO companies. Mike is a highly respected leader in neuroscience drug development and sits on multiple advisory boards. He was selected by the FDA to be the industry representative for advisory committees of the Office of Neuroscience.

Agenda Sessions

  • The Use of Oligonucleotides in the Treatment of Neurodegenerative Disorders

    4:45pm